Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
20.50
-1.70 (-7.66%)
At close: Nov 21, 2024, 4:00 PM
19.48
-1.02 (-4.98%)
After-hours: Nov 21, 2024, 5:18 PM EST
Oruka Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Oruka Therapeutics stock have an average target of 43.6, with a low estimate of 40 and a high estimate of 49. The average target predicts an increase of 112.68% from the current stock price of 20.50.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ORKA stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Sep '24 | Oct '24 | Nov '24 |
---|---|---|---|
Strong Buy | 2 | 4 | 4 |
Buy | 2 | 2 | 2 |
Hold | 0 | 0 | 0 |
Sell | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 |
Total | 4 | 6 | 6 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $45 | Strong Buy | Reiterates | $45 | +119.51% | Oct 31, 2024 |
Stifel | Stifel | Strong Buy Initiates $49 | Strong Buy | Initiates | $49 | +139.02% | Oct 11, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $45 | Strong Buy | Initiates | $45 | +119.51% | Oct 7, 2024 |
Leerink Partners | Leerink Partners | Buy Initiates $44 | Buy | Initiates | $44 | +114.63% | Sep 17, 2024 |
Leerink Swann | Leerink Swann | Buy Initiates $44 | Buy | Initiates | $44 | +114.63% | Sep 17, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock
Revenue Forecast
No data available
Revenue Growth
No data available
EPS Forecast
No data available
EPS Growth
No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.